SPACA6P-AS

Across TCGA pan-cancer cohorts, SPACA6P-AS Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SPACA6P-AS data layer compared with 22 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher SPACA6P-AS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated SPACA6P-AS expression acts as an unfavorable survival marker.

ESCA, BLCA, and SKCM are the cancer types where SPACA6P-AS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.124	0.526	.002	18	view →
BLCA	OS	Median	All	0.188	0.710	.004	15	view →
SKCM	OS	Median	All	0.216	0.781	.001	15	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.276	0.697	.040	3	view →
LIHC	DFS	Median	All	0.140	0.555	.017	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SPACA6P-AS–ESCA (DFS)

Open the ESCA breakdown →